ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 20th World Congress on Gastrointestinal Cancer

 

20-23 June, 2018 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-O Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors Funda Meric-Bernstam Received Received
  1-LB Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH) Mia Chen Received Received
  2-LB Overall survival results from a phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS) Josep Tabernero Received Received
  2-PD A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis Angelo Cho Received Received
  3-PD Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor Junichi Arita Received Received
  3-P Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma Jia Wei Received Received
  4-P MicroRNAs and CDH1 regulation in intestinal-type gastric cancer chiara molinari Received Received
  5-O A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer Yoshinori Kagawa Received Received
  5-P Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospital Luis Corrales-Rodriguez Received Received
  5-PD Post-Operative Venous Thromboembolism and Mortality in Patients with Pancreatic Cancer Surgery Kaushal Majmudar Received Received
  6-PD Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients Maud Marques Received Received
  6-P Personalization of treatment for patients with stomach cancer using molecular genetic markers Igor Bykov Received Received
  7-O Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cetiri: Final results and translational analyses of the CRICKET study by GONO Daniele Rossini Received Received
  8-P Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016 Mari Lhmus Received Received
  8-PD Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting Mirella Giordano Received Received
  9-PD Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade Takeshi Yamada Received Received
  9-P Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fez hayat erraichi Received Received
  10-PD REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis Kohei Shitara Received Received
  10-P Berberine inhibits the migration and invasion via AMPK/HNF4a pathway in gastric cancer Qian Hu Received Received
  11-P Estrone is a marker of the pre-metastatic niche in patients with stomach cancer Oleg Kit Received Received
  11-PD SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results Tomoko Miura Received Received
  11-O Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) Philippe Merle Received Received
  12-PD Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies Katarina Gluic Received Received
  12-O Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study Katarina Gluic Received Received
  13-PD Usefulness of colonic tattooing using ICG in patients with colorectal tumors Jae Ho Park Received Received
  13-O Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study Sarah Novack Received Received
  13-P Redox forms of glutathione mark the aggressiveness of stomach cancer Irina Goroshinskaya Received Received
  14-P Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layer byoung wook bang Received Received
  14-O Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network study Tanios Bekaii-Saab Received Received
  15-P Patient derived xenografts from American minority gastric cancer patients Sam Wang Received Received
  16-PD Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab Vilma Pacheco-Barcia Received Received
  16-O First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study Filippo Pietrantonio Received Received
  17-O FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO Federica Marmorino Received Received
  17-P Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018 Elena-Carmen Bosteanu Received Received
  17-PD Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC) Elena Ongaro Received Received
  18-PD Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study Katleen Janssens Received Received
  19-P Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt Ahmed Gaballah Received Received
  19-PD RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles U.S.FDA BB-IND 10091 Angelica Nazarian Received Received
  20-P Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinoma Vasiliki Michalaki Received Received
  21-P Molecular profiling of gastrointestinal cancer PANAGIOTIS PARSONIDIS Received Received
  22-O Phase II study evaluating trifluridine/tipiracilbevacizumab and capecitabinebevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis Eric Van Cutsem Received Received
  23-P Gastrointestinal stromal tumours: Retrospective review of an institution Helena Magalhaes Received Received
  24-P Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma Oleg Kit Received Received
  26-P Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head Elena Frantsiyants Received Received
  27-P Polymer hydrogels as innovative carriers for anticancer therapy Magdalena K&281;dzierska Received Received
  28-P Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-?B signaling to attenuate invasion and metastasis of gallbladder carcinoma Yu Shi Received Received
  28-O Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration Shintaro Takeuchi Received Received
  30-P Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer program Joseph Jr Bernard Received Received
  31-P Morbidity trends for ed gastrointestinal cancers in Poland and the costs of treatment Miroslaw Jarosz Received Received
  33-P Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients Cristina Morelli Received Received
  35-P Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXM1 signaling Liankang Sun Received Received
  36-P High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma Sally Temraz Received Received
  40-P Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiation Khin Ni Sann Received Received
  41-P Prognostic impact of C-reactive protein / albumin ratio in locally advanced esophageal cancer Joana Simes Received Received
  42-P Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FU Nuno Tavares Received Received
  43-P Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patients Hyun Ho Choi Received Received
  44-P Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerología, México Jesus Zamora Moreno Received Received
  45-P Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital Arantzazu Barquín García Received Received
  48-P Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centre Naveen kumar Received Received
  52-P A phase 3 study of chemotherapy pembrolizumab versus chemotherapy placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 Ken Kato Received Received
  53-P Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer Ahmed Gaballah Received Received
  54-P Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram IRENE PECORA Received Received
  55-P Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations Naama Halpern Received Received
  56-P Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinoma Allan Ramos-Esquivel Received Received
  57-P Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics Fabiola Cecchi Received Received
  58-P The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer Nieves Martinez Lago Received Received
  60-P Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissection Do Hoon Kim Received Received
  63-P The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in Korea SANG MIN LEE Received Received
  64-P Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m2 (nacG-SOX130) in stage III gastric cancer Sayuri Konishi Received Received
  65-P Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit Nazim Abbas Received Received
  67-P Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective study Takatsugu Ogata Received Received
  69-P Associated factors with overlooked multiple synchronous gastric epithelial neoplasia Cheol Woong Choi Received Received
  72-P Is the prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea? Suyun Oh Received Received
  73-P Prognostic factors for gastric cancer after curative gastrectomy Sarra Karrit Received Received
  74-P Outcome and prognostic factors of gastric cancer in Tunisia Sarra Karrit Received Received
  78-P Management, outcome and prognostic factors of metastatic gastric cancer Sarra Karrit Received Received
  79-P Efficacy and safety of nivolumab monotherapy for metastatic gastric cancer Kohei Akiyoshi Received Received
  80-P Gastric cancer in young patients under the age of 45 years old: A comparative study with older patients Sarra Karrit Received Received
  81-P Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF) Ana Rolo Received Received
  82-P Neoadjuvant chemotherapy in gastric cancer Adda Bounedjar Received Received
  85-P The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy Yusuke Sasaki Received Received
  86-P Treatment and testing patterns among patients with HER2 advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States Lisa Hess Received Received
  88-P Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patients Renato Cannizzaro Received Received
  89-P Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors? Renato Cannizzaro Received Received
  90-P Ethnic and racial disparities among young patients with noncardia gastric cancer Matthew Porembka Received Received
  95-P A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting Xianmeng Wu Received Received
  96-P A phase 3 study of chemotherapy pembrolizumab vs chemotherapy placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 Yung-Jue Bang Received Received
  97-P SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancer Jan Eick Received Received
  98-P Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.) LISA HESS Received Received
  101-P HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma Hugo Siedlecki Received Received
  102-P A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year period Nicholas Wreglesworth Received Received
  103-P The prospective multicenter study of relation between 5-HIAA / substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy Tetsuhito Muranaka Received Received
  105-P Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancer João Fonseca Received Received
  109-P Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapy Laura Morrison Received Received
  110-P Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapy Irena Oblak Received Received
  114-P The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experience Banu Ozturk Received Received
  116-P A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumors Isabel Domingues Received Received
  117-P 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience Francisca Elena Marti Marti Received Received
  118-P Chemoradiation for anal canal carcinoma in a comprehensive cancer center: Retrospective cohort study João Dias Received Received
  119-P The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302) Tatsuya Ioka Received Received
  121-P Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy Nobumichi Takeuchi Received Received
  123-P Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapy TICIANA MARIA RANGEL DE PAULA PESSOA Received Received
  124-P De novo malignancies in patients after liver transplantation: A single centre experience Klara Chmelova Received Received
  125-P Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapy Mathieu DHondt Received Received
  126-P Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern India Ashutosh Mishra Received Received
  127-P Impact of lymph node positivity on overall survival in operable gall bladder cancer: An experience from tertiary cancer care centre from Northern India Ashutosh Mishra Received Received
  128-P Surgical resection of primary tumor site is prolonged survival in metastatic pancreatic neuroendocrine carcinoma Tingting Feng Received Received
  129-P Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation Se Hyun Jang Received Received
  130-P A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies Jia Wei Received Received
  131-P Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY Han Jo Jeon Received Received
  132-P Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabineplacebo versus gemcitabineevofosfamide and identifies candidate targets Valeriy Domenyuk Received Received
  133-P The use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and CA 19-9 as prognostic markers for locally advanced pancreatic cancer Meabh McNulty Received Received
  136-P Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen Alessandro Parisi Received Received
  137-P Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients Yasushi Tsuji Received Received
  138-P Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience Cristina Saavedra Received Received
  139-P HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer Satoshi Yuki Received Received
  141-P PanCO: An open-label, single-arm pilot study of Oncosil in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabinenab-paclitaxel chemotherapies Thomas Maher Received Received
  142-P Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer Maria Drizou Received Received
  143-P Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction Mitsuhito Sasaki Received Received
  147-P Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma Meabh McNulty Received Received
  149-P Risk factors and epidemiological features of pancreatic cancer in Iran Akram Pourshams Received Received
  154-P Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study Gemma Bruera Received Received
  156-P Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology center Helena Magalhaes Received Received
  157-P Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma Vasiliki Michalaki Received Received
  158-P Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19-9 in predicting outcome for metastatic pancreatic cancer Adarsh Das Received Received
  159-P Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine nab-paclitaxel Vivaldi Caterina Received Received
  160-P Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice Gerarrd Carot-Sans Received Received
  161-P Folfirinox versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study IN RAE CHO Received Received
  162-P Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors Beatriz Antón Received Received
  163-P Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb Juraj Prejac Received Received
  164-P Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival Vilma Pacheco-Barcia Received Received
  165-P Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer DANIEL HOLYOAKE Received Received
  168-P Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model Azra Sahmanovic Hrgovcic Received Received
  170-P Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists practice choices Emily Meier Received Received
  171-P Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in Brazil TICIANA MARIA RANGEL DE PAULA PESSOA Received Received
  172-P Treatment modalities and prognostic factors of pancreatic cancer: A retrospective study Imtinane Belaid Received Received
  175-P Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancer won kyung cho Received Received
  176-P Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute study Ahmed Nagy Received Received
  177-P Epidemiology of pancreatic cancer Imtinane Belaid Received Received
  180-P Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis Sally Temraz Received Received
  181-P Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survival Bojan ILIJEVEC Received Received
  184-P CanStem 111P Trial: A Phase 3 Study of Napabucasin (NAPA) Plus Nab-Paclitaxel (nPTX) With Gemcitabine (Gem) in Adult Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC) Natalie Johnson Received Received
  185-P PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma Hugo Siedlecki Received Received
  187-P Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer Margarita Kruchinina Received Received
  189-P Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancer Wenji Yan Received Received
  191-P Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experience TANVI SOOD Received Received
  193-P RAS status in Algerian metastatic colorectal cancer Assia Bensalem Received Received
  194-P Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression Foteinos- Ioannis Dimitrakopoulos Received Received
  195-P Cost of illness for colorectal cancer at low middle income countries Egypt case Abdalla Abotaleb Received Received
  197-P Repurposing ponatinib for the treatment of colorectal cancer Rodney Luwor Received Received
  199-P Colorectal cancer screening in Flanders: Advances in personalised screening Wessel van de Veerdonk Received Received
  201-P Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin era Darragh Connell Received Received
  203-P Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 cases Khadija Darif Received Received
  204-P Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 cases Khadija khadija Received Received
  205-P Preoperative short course of radiotherapy in ed high risk patients Monica Caro Gallarin Received Received
  206-P Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers Gemma Bruera Received Received
  208-P Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts) Michalis Karamouzis Received Received
  209-P P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab Marco Puzzoni Received Received
  210-P Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus III Ivan Tonev Received Received
  211-P Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab Alessandro Passardi Received Received
  212-P CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer Abiola Fatimilehin Received Received
  213-P An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities Fotheringham Susan Received Received
  214-P Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators? Katarina Gluic Received Received
  216-P Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method Michèle Boisdron-Celle Received Received
  217-P ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer Nils Brnner Received Received
  221-P Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs Jacopo Giuliani Received Received
  223-P NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons Satoshi Yuki Received Received
  224-P Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics Dai Manaka Received Received
  225-P The role of maintenance therapy in the first line treatment of metastatic colorectal cancer Danila Gridnev Received Received
  226-P HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment Michio Nakamura Received Received
  227-P Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital Cristina Saavedra Received Received
  228-P VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC) Hideaki Bando Received Received
  230-P Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors Renata Biernacka Received Received
  231-P Clinical significance of microsatellite instability in gender-dependent patients with right-sided colorectal cancer Ji Hun Choi Received Received
  232-P Efficacy of adjuvant chemotherapy for elderly patients with colon cancer Maria Villamayor Received Received
  233-P Trifluridine/ tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study Hironaga Satake Received Received
  234-P Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC) Mary Smith Received Received
  235-P Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndrome Keisuke Hara Received Received
  236-P Clinical and pathological features in colorectal cancer associated to Lynch syndrome OLIVER HIGUERA Received Received
  237-P Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial Marco Stellato Received Received
  238-P Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC) Juan José Serrano Domingo Received Received
  239-P Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary Hospital Roberto Martín Huertas Received Received
  240-P Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital. Elena Corral de la Fuente Received Received
  242-P International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer Mladjan Protic Received Received
  243-P Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy AKIHITO TSUJI Received Received
  244-P Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study) Hironaga Satake Received Received
  246-P Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients Mercedes Martinez Villacampa Received Received
  250-P Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria zoubida Behourah Received Received
  251-P The prognostic ad predictive value of primary tumor sidedness in the mCRC pts Banu Ozturk Received Received
  252-P The evaluation of liver resection for colorectal cancer liver metastases Masaichi Ogawa Received Received
  253-P A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study Masaru Iwata Received Received
  256-P Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective study Yi-Hsin Liang Received Received
  257-P Improvement of metastatic colorectal cancer patient survival: a Single institution experience Elisabetta Fenocchio Received Received
  258-P HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib Satoshi Yuki Received Received
  259-P Variability of current global practice patterns in the management of metastatic colorectal cancer Krista Marcello Received Received
  260-P Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap Liliana Borsellino Received Received
  261-P HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index Satoshi Yuki Received Received
  262-P Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancer Giuseppe Colloca Received Received
  264-P HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction Satoshi Yuki Received Received
  265-P Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG) Renata Peixoto Received Received
  266-P Retrospective analysis from efficacy with trifluridine-tipiracil (TAS-102) in patients with metastatic colorectal cancer and possible clinical factors associated with a greater benefit: experience at seven hospitals Jesús Miranda Received Received
  267-P The prognostic impact of sidedness in RAS wild-type colorectal cancer Nuno Tavares Received Received
  269-P Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016 Mikhail Fedyanin Received Received
  270-P Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC) Mikhail Fedyanin Received Received
  271-P Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina) Juan Manuel OConnor Received Received
  272-P Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancer Zorana Maravic Received Received
  273-P Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study Zorana Maravic Received Received
  274-P The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens) Anastasia Mochalova Received Received
  275-P Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/Irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017 Gregory Wilson Received Received
  276-P Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study Ismael Ghanem Received Received
  277-P Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study) Carles PERICAY Received Received
  279-P Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center Carolina Sales Received Received
  281-P The impact of primary tumor location in patients with resected colorectal liver metastasis Vilma Pacheco-Barcia Received Received
  282-P RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomo-clinical factors? mariam haffadi Received Received
  283-P Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer Takada Shinya Received Received
  284-P Characteristics of colorectal cancer in the elderly patients about 60 cases Hanane Fatima Zahra Aliane Received Received
  285-P Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence Emily Meier Received Received
  286-P Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists knowledge and competence Emily Meier Received Received
  287-P Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence Emily Meier Received Received
  288-P Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia Lisi Elizabeth Lim Received Received
  289-P Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases Naveeshini Nair Chandran Received Received
  291-P The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status Pina Ziranu Received Received
  292-P A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer DEREGULATE study Kiyotaka Kawaguchi Received Received
  293-P Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program Andres Jorge Schmilovich Received Received
  294-P Multicenter phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) Takeshi Kato Received Received
  295-P A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer Owen Murray Received Received
  297-P CanStem 303C Trial: A Phase 3 Study of Napabucasin (NAPA) in CombinationWith 5-Fluorouracil (5-FU), Leucovorin, and Irinotecan (FOLFIRI) in AdultPatients With Previously Treated Metastatic Colorectal Cancer (mCRC) Natalie Johnson Received Received
  299-P Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in Peru Rodrigo Motta Received Received
  300-P Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): preliminary results Paola Simona Ravenda Received Received
  301-P CRP / albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancer Tarkan Yetisyigit Received Received
  302-P Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better? Xavier Hernández-Yague Received Received
  303-P Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospital MARTALENA PURBA Received Received
  304-P Preoperative chemoradiation in locally advanced rectal cancer: A single center experience Liliana Oliveira Received Received
  305-P The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excision SooYoon Sung Received Received
  307-P Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiation Gyu Sang Yoo Received Received
  309-P Quality improvement in the management of rectal cancer in a large healthcare system in the United States William Sause Received Received
  311-P Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancer Ahmed Nagy Received Received
  313-P Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancer Abror Abdujapparov Received Received
  314-P Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy Laura Díaz Received Received
  315-P The role of palliative re-irradiation in management of rectal cancer mohan hingorani Received Received
  316-P Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy? Mateusz Spalek Received Received
  317-P A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer Rajarshi Roy Received Received
  319-P Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer Vaneja Velenik Received Received
  320-P Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer Susan Higgins Received Received
  321-P Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma Hanane Fatima Zahra Aliane Received Received
  322-P First study in North Africa: Screening colorectal cancer mazouzi chahira Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
08:24
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 20th World Congress on Gastrointestinal Cancer

 

20-23 June, 2018 Barcelona
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 20/06/2018 TO 20/06/2019
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.20wcgic.2018 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 17/06/2018
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster








PosterSessionOnline
Logo Draft
 
Logo Cert